Cancer of unknown primary: Addressing the communicative, ethical and medical challenges in clinical practice - A perspective from palliative care and supportive oncology

Progress in Palliative Care

Volumn 18, Issue 5, 2010, Pages 291-296

  Ryan, Richella C ^a   Lawlor, Peter G ^b   Walshe, Janice M ^c  

^a Our Lady's Hospice Ltd Dublin   (Ireland)

^b BRUYÈRE RESEARCH INSTITUTE   (Canada)

^c ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

cancer of unknown primary; communication; ethical challenges; palliative care; supportive oncology

Indexed keywords

ANTINEOPLASTIC AGENT; METOCLOPRAMIDE; OXYCODONE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CASE REPORT; CLINICAL PRACTICE; FEMALE; HUMAN; INTERPERSONAL COMMUNICATION; LIVER BIOPSY; MEDICAL ETHICS; ONCOLOGY; PALLIATIVE THERAPY;

EID: 77957153847     PISSN: 09699260     EISSN: 1743291X     Source Type: Journal    
DOI: 10.1179/096992610X12775428636782     Document Type: Article

References (28)

1. Lau F, Cloutier-Fisher D, Kuziemskey C et al. A systematic review of prognostic tools for estimating survival time in palliative care. J Palliat Care 2007; 23: 93-112.
2. Kirsten F, Chi CH, Leary JA et al. Metastatic adeno or undifferentiated carcinoma from an unknown primary site - natural history and guidelines for identification of treatable subsets. Q J Med 1987; 62: 143-161.
3. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39: 1990-2005.
4. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 2004; 100: 1776-1785.
5. Briasoulis E, Pavlidis N, Felip E. Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment, follow-up. Ann Oncol 2008; 19: 106-107.
6. G Pentheroudakis, Briasoulis E, Pavlidis N. Cancer of unknown primary or missing biology? Oncologist 2007; 12: 418-425.
7. Park SY, Kim BH, Kim JH et al. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 2007; 131: 1561-1567.
8. Dennis JL, Hividsten TR,Wit EC et al.Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005; 11: 3766-3772.
9. Horlings HM, Van Laar RK, Kerst JM et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008; 26: 4435-4441.
10. Oien KA, Jeffry Evans TR. Raising the profile of cancer of unknown primary. J Clin Oncol 2008; 26: 4373-4375.
11. Varadhachary GR, Talantov D, RaberMN et al.Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008; 26: 4442-4448.
12. Van de Wouw AJ, Jansen RLH, Speel EJM, et al. The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 2003; 14: 191-196.
13. Hilten HF. Unknown primary tumours. Postgrad Med J 2000; 76: 690-693.
14. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary; from autopsy to microarray. Eur J Cancer 2007; 43: 2026-2036.
15. Le Chevalier T, Cvitkovi E, Caille P et al. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988; 148: 2035-2039.
16. Nystrom JS, Weiner JM, Heffelfinger-Juttner J et al. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 1977; 4: 53-58.
17. Briasoulis E, Pavlidis N. Cancer of unknown primary origin. Oncologist 1997; 2: 142-152.
18. Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev 2008; 34: 693-700.
19. Yakushiji S, Ando M, Yonemori K. Cancer of unknown primary site: review of consecutive cases at the National Cancer Centre Hospital of Japan. Int J Clin Oncol 2006; 11: 421-425.
20. Hogan BA, Thorton FJ, BranniganMet al. Hepatic metastases from unknown primary neoplasm (UPN): survival, prognostic indicators and value of extensive investigations. Clin Radiol 2002; 57: 1073-1077.
21. Bugat R, Batallard A, Lesimple T et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site. Br J Cancer 2003; 89: 59-66.
22. Shaw PH, Adams R, Jordan C, Crosby TDL. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clin Oncol 2007; 19: 87-95.
23. Pentheroudakis G, Brasoulis E, Haralambos P et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary; a multicentre Hellenic Co-operative Oncology Group phase 2 study. Acta Oncol 2008; 47: 1148-1155.
24. Jadeja J, Legha S, Burgess M et al. Combination chemotherapy with 5-fluorouracil, adriamycin, cyclophosphamide, and cisplatinum in the treatment of adenocarcinoma of unknown primary and undifferentiated carcinomas. Proc Am Soc Clin Oncol 1983; 2: C-926.
25. Boyland L. Patients experience of carcinoma of unknown primary site: dealing with uncertainty. Palliat Med 2008; 22: 177-183.
26. Kite S, Hicks F. Palliative medicine for the cancer and non-cancer patient. Clin Med 2005; 5: 626-629.
27. Robertson R, Campbell NC, Smith S. Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas. Br J Cancer 2004; 40: 1479-1485.
28. Abrams RD, Finesinger JE. Guilt reactions in patients with cancer. Cancer 1953; 6: 474-482.